Eculizumab Therapy for Chronic Complement-Mediated Injury in Kidney Transplantation

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

March 31, 2011

Primary Completion Date

February 28, 2015

Study Completion Date

February 28, 2015

Conditions
Kidney; Complications, Allograft
Interventions
DRUG

eculizumab

"* Eculizumab Induction 600mg IV every 7 days for 4 doses~* Eculizumab 900mg IV 7 days later~* Eculizumab Maintenance 900mg IV every 14 days for total of 26 weeks"

Trial Locations (1)

06520

Yale University, New Haven

Sponsors
All Listed Sponsors
collaborator

Alexion Pharmaceuticals, Inc.

INDUSTRY

lead

Sanjay Kulkarni

OTHER